Billionaire Ken Griffin’s 10 Midcap Stock Picks with Huge Upside Potential

4. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stock Upside Potential:   45.88%

Citadel Investment Group’s Stake: $346,451,879

Neurocrine Biosciences, Inc. operates as a developer, discoverer, and marketer of pharmaceuticals for neuroendocrine, neuropsychiatric, and neurological disorders. Its major product candidates include INGREZZA, Efmody capsules, Orilissa tablets, Oriahnn capsules, ALKINDI, and CRENESSITY.

The firm was upgraded by RBC Capital Markets from Sector Perform to Outperform, highlighting the recent market downturn as an attractive buying opportunity. However, the price target was adjusted by RBC analyst Brian Abrahams from $138 to $137, anticipating short-term fluctuations due to the latest quarter earnings and long-term uncertainty surrounding Medicare drug price talks.

RBC analysts think that the current share price is a good entry point for investors looking for a reliable biotech.

RBC Capital Markets’ analyst Brian Abrahams stated:

Broader sector selloff and market downside has brought the stock to levels well below fundamental fair value, given an Ingrezza commercial franchise that we expect to be relatively solid and durable long term.

The company also reaffirmed its 2025 guidance after beating top-line estimates in the most recent quarter. Aided by ongoing direct-to-consumer initiatives and an expanded sales force, Neurocrine anticipates INGREZZA sales to reach $2.5 billion to $2.6 billion for the full year. Regardless of potential competition, this guidance demonstrates continued growth. Due to clinical adoption factors and delays in reimbursement processes, the company expects CRENESSITY’s revenue to increase gradually. Moreover, Phase 3 trials for osavampator and NBI-568 are ongoing, with the firm setting aside $60 million to advance its product pipeline during 2025.